Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Trastuzumab (DB00072)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00004883Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2Treatment